Cargando…
P300 latency changes in patients with mild cognitive impairment after taking choline alphoscerate; A preliminary study
Choline alphoscerate in clinical studies improved cognitive dysfunction in dementia, but it did not show any clear clinical benefit on mild cognitive impairment (MCI). There is limited evidence of neuropsychological markers in showing the effects of cholinergic precursors in MCI. Object of this prel...
Autores principales: | Han, Su-Hyun, Jeong, Hae-Bong, Park, Kwang-Yeol, Shin, Hae-Won, Youn, Young Chul, Kim, SangYun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007142/ https://www.ncbi.nlm.nih.gov/pubmed/29928709 http://dx.doi.org/10.1016/j.ensci.2018.04.004 |
Ejemplares similares
-
Choline and Choline alphoscerate Do Not Modulate Inflammatory Processes in the Rat Brain
por: Tayebati, Seyed Khosrow, et al.
Publicado: (2017) -
Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study
por: Kim, Yeong Jin, et al.
Publicado: (2022) -
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis
por: Sagaro, Getu Gamo, et al.
Publicado: (2023) -
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial
por: Salvadori, Emilia, et al.
Publicado: (2021) -
Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer’s Disease
por: Carotenuto, Anna, et al.
Publicado: (2022)